OBJECT DRUGS

Tyrosine Kinase Inhibitors (CYP3A4 Substrates):

• Crizotinib (Xalkori)
• Dasatinib (Sprycel)
• Erlotinib (Tarceva)
• Gefitinib (Iressa)
• Imatinib (Gleevec)
• Lapatinib (Tykerb)
• Nilotinib (Tasigna)
• Pazopanib (Votrient)
• Sorafenib (Nexavar)
• Sunitinib (Sutent)

PRECIPITANT DRUGS

Enzyme Inducers:

• Barbiturates
• Bosentan (Tracleer)
• Carbamazepine (Tegretol, etc.)
• Efavirenz (Sustiva)
• Nevirapine (Viramune, etc.)
• Oxcarbazepine (Trileptal, etc.)
• Phenytoin (Dilantin, etc.)
• Primidone (Mysoline)
• Rifabutin (Mycobutin)
• Rifampin (Rifadin, etc.)
• Rifapentine (Priftin)
• St. John's Wort

Comment:

Although data are limited, these enzyme inducers may decrease the plasma levels of tyrosine kinase inhibitors. Reduction in the expected antineoplastic activity or resistance may occur.

Class 3: Assess Risk & Take Action if Necessary

• Monitor: Monitor for altered antineoplastic response if the CYP3A4 inducer is initiated, discontinued, or changed in dosage.